Brendan B. Springstubb - 04 Jun 2026 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Reporting relationship: Director
Issuer ticker: EVH
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:21:24 UTC
Prior SEC filing: 19 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Weinberg, Attorney-in-fact

Key filing fact

Brendan B. Springstubb filed Form 4 for Evolent Health, Inc. (EVH) on 08 Jun 2026.

Key facts

This page summarizes Brendan B. Springstubb's Form 4 filing for Evolent Health, Inc. (EVH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jun 2026, 16:21.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001687656 Primary reporting owner

Springstubb Brendan B

Relationship: Director
Address: C/O EVOLENT HEALTH, INC., 1812 N. MOORE ST., STE. 1705, ARLINGTON
Signature: /s/ Jonathan Weinberg, Attorney-in-fact
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVH transaction

Class A Common Stock

Award

Transaction value
Shares: +41,096
Change %: +70%
Price: $0.000000^*
Shares after: 99,917
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units granted to Mr. Springstubb pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

Footnote F2

Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.